T. Hippel James's most recent trade in Bio-Techne Corp was a trade of 62,000 Common Stock done at an average price of $47.6 . Disclosure was reported to the exchange on May 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 05 May 2026 | 62,000 | 210,625 (0%) | 0% | 47.6 | 2,951,200 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 62,000 | 62,068 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.68 per share. | 05 May 2026 | 56,955 | 153,670 (0%) | 0% | 56.7 | 3,228,209 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 62,000 | 124,068 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 62,000 | 204,722 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.58 per share. | 22 Apr 2026 | 56,097 | 148,625 (0%) | 0% | 58.6 | 3,286,162 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 13,159 | 143,042 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 13,159 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.57 per share. | 03 Nov 2025 | 11,865 | 142,722 (0%) | 0% | 62.6 | 742,393 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 11,545 | 23,089 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 11,545 | 154,587 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 37,632 | 37,632 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 29,420 | 29,420 | - | - | Performance Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 14,710 | 14,710 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 4,010 | 131,809 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 4,010 | 8,021 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.60 per share. | 15 Aug 2025 | 1,926 | 129,883 (0%) | 0% | 53.6 | 103,234 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2025 | 168,620 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 29 Jul 2025 | 168,620 | 275,230 (0%) | 0% | 44.3 | 7,474,925 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.55 per share. | 29 Jul 2025 | 147,431 | 127,799 (0%) | 0% | 58.5 | 8,632,085 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 34,634 | 34,634 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 13,159 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 113,085 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 6,475 | 106,610 (0%) | 0% | 75.3 | 487,632 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 32,417 | 32,417 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 24,062 | 24,062 | - | - | Performance Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 12,031 | 12,031 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 53,000 | 53,867 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 02 Aug 2024 | 53,000 | 136,002 (0%) | 0% | 31.3 | 1,656,780 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.35 per share. | 02 Aug 2024 | 36,076 | 99,926 (0%) | 0% | 82.4 | 2,970,859 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 23 Jul 2024 | 35,000 | 107,284 (0%) | 0% | 31.3 | 1,094,100 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jul 2024 | 35,000 | 106,867 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.77 per share. | 23 Jul 2024 | 24,282 | 83,002 (0%) | 0% | 77.8 | 1,888,411 | Common Stock |
| Bio-Techne | T. James Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 19 Dec 2023 | 47,289 | 104,850 (0%) | 0% | 31.3 | 1,478,254 | Common Stock |
| Bio-Techne | T. Hippel James | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 47,289 | 141,867 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | Hippel T. James | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.42 per share. | 19 Dec 2023 | 32,966 | 71,884 (0%) | 0% | 77.4 | 2,552,228 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 45,923 | 45,923 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | T. Hippel James | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 37,314 | 37,314 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 34,442 | 34,442 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | Hippel James T. | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 13,865 | 13,865 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 12,798 | 12,798 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 63,896 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 6,335 | 57,561 (0%) | 0% | 82.2 | 520,547 | Common Stock |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 11,305 | 11,305 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 8,479 | 8,479 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 2,728 | 2,728 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 14,693 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,938 | 12,755 (0%) | 0% | 383.0 | 742,196 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 8,822 | 47,589 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 8,822 | 19,577 (0%) | 0% | 125.0 | 1,103,191 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.61 per share. | 01 Nov 2021 | 3,566 | 16,011 (0%) | 0% | 525.6 | 1,874,318 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 526.50 per share. | 01 Nov 2021 | 2,880 | 13,131 (0%) | 0% | 526.5 | 1,516,321 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 527.50 per share. | 01 Nov 2021 | 1,433 | 11,698 (0%) | 0% | 527.5 | 755,903 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 528.55 per share. | 01 Nov 2021 | 943 | 10,755 (0%) | 0% | 528.6 | 498,427 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 200 | 47,389 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.10 per share. | 01 Nov 2021 | 200 | 10,755 (0%) | 0% | 525.1 | 105,020 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 200 | 10,955 (0%) | 0% | 125.1 | 25,010 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2021 | 662 | 56,411 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.23 per share. | 28 Oct 2021 | 662 | 10,755 (0%) | 0% | 525.2 | 347,704 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Oct 2021 | 662 | 11,417 (0%) | 0% | 125.0 | 82,783 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.18 per share. | 28 Oct 2021 | 100 | 10,755 (0%) | 0% | 525.2 | 52,518 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 10,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 02 Sep 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 507.22 per share. | 02 Sep 2021 | 9,993 | 10,862 (0%) | 0% | 507.2 | 5,068,600 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 509.14 per share. | 02 Sep 2021 | 7 | 10,855 (0%) | 0% | 509.1 | 3,564 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 10,134 | 10,134 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 06 Aug 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 10,000 | 10,000 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 7,600 | 7,600 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 477.69 per share. | 06 Aug 2021 | 5,200 | 15,655 (0%) | 0% | 477.7 | 2,484,002 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 3,383 | 12,520 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 3,383 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,945 | 1,945 | - | - | Restricted Stock Units | |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 478.58 per share. | 06 Aug 2021 | 1,800 | 13,855 (0%) | 0% | 478.6 | 861,444 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 1,665 | 10,855 (0%) | 0% | 481.8 | 802,230 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 479.96 per share. | 06 Aug 2021 | 1,300 | 12,555 (0%) | 0% | 480.0 | 623,954 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 480.66 per share. | 06 Aug 2021 | 700 | 11,755 (0%) | 0% | 480.7 | 336,462 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 481.61 per share. | 06 Aug 2021 | 300 | 11,455 (0%) | 0% | 481.6 | 144,482 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 483.62 per share. | 06 Aug 2021 | 300 | 11,155 (0%) | 0% | 483.6 | 145,085 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 484.98 per share. | 06 Aug 2021 | 300 | 10,855 (0%) | 0% | 485.0 | 145,494 | Common Stock |
| Bio-Techne | James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 480.70 per share. | 06 Aug 2021 | 100 | 12,455 (0%) | 0% | 480.7 | 48,070 | Common Stock |